However, even in the ALSYMPCA trial, only 63% of patients received the maximum six cycles of Radium-223, whereas in the real-world setting patients are typically older with more comorbidities than those participating in clinical trials. As such, the objective of this study was to assess the real-world use of Radium-223 in four Ontario cancer centers.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
In conclusion, in an older, real world population with comparable disease characteristics to those enrolled in ALSYMPCA, Radium-223 was safely administered but the proportion of patients receiving all six cycles of treatment was low (and lower compared to patients in ALSYMPCA). Future pooled analyses on a larger scale would increase the sample size to allow for analysis of factors predicting early Radium-223 termination.
Presented By: Urban Emmenegger, MD, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
Co-Authors: Sierra Cheng, Leigha Rowbottom, Rachel McDonald, Ronald Chow, Neil E. Fleshner, Pawel Zalewski, Anil Kapoor, Edward Chow
Written By: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre Twitter: @zklaassen_md at the 72nd Canadian Urological Association Annual Meeting - June 24 - 27, 2017 - Toronto, Ontario, Canada
1. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013 Jul 18;369(3):213-223.